Quick answer
What is Somatropin?
Built from index records dated 2026-10-09 to 2026-10-13 Compiled by an automated pipeline, checked by The Peptide Observer editorial desk. No qualified clinical reviewer. How this site works
Somatropin is not a peptide, grouped on this site under Growth factors and growth hormone-derived compounds, and the 12 research records kept here are 8 from trials in people and 4 that do not state what kind of study it is.
The literature search returned 440 records. This site keeps 12 of them, which is 2.7 per cent of what came back.
What it is
Somatropin is indexed here despite not being a peptide, because the same research literature and the same searches cover it. This site puts it in the Growth factors and growth hormone-derived compounds group.
Recombinant human growth hormone; the retrieved records study it as replacement of the endogenous hormone, with body composition and metabolic endpoints.[1, 2]
Stated in the titles of the cited 1989 New England Journal of Medicine and 2013 Journal of Clinical Endocrinology and Metabolism papers.
What kind of records
No public chemistry record was found under this name, so the entry describes a preparation, a protein or a mixture rather than one defined molecule.
That sentence is produced by counting, not by reading. What was counted: PubChem returned no compound record for this name, so the subject is a preparation, protein or mixture rather than a defined small molecule; identity fields are unsourced.
What this does not settle
- What it does in a body. Counting records is not reading them, and nothing here has been read in full.
- Whether it causes harm. No adverse-effect row was taken from any source for this entry.
- How long it lasts. No pharmacokinetics source was retrieved for this entry.
- What the other 428 retrieved records say. They are not in this index.
The longer explanation
Where this comes from
The records cited above, in full.
- The effects of treatment with recombinant human growth hormone on body composition and metabolism in adults with growth hormone deficiency. The New England journal of medicine (1989). pmid:2687691
- GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. The Journal of clinical endocrinology and metabolism (2013). pmid:23543664